176 related articles for article (PubMed ID: 37169533)
21. Novel PET tracers: added value for endocrine disorders.
Bergeret S; Charbit J; Ansquer C; Bera G; Chanson P; Lussey-Lepoutre C
Endocrine; 2019 Apr; 64(1):14-30. PubMed ID: 30875057
[TBL] [Abstract][Full Text] [Related]
22. Automated production of [
Lindner S; Simmet M; Gildehaus FJ; Jurkschat K; Wängler C; Wängler B; Bartenstein P; Schirrmacher R; Ilhan H
Nucl Med Biol; 2020; 88-89():86-95. PubMed ID: 32828007
[TBL] [Abstract][Full Text] [Related]
23. Clinical applications of Gallium-68.
Banerjee SR; Pomper MG
Appl Radiat Isot; 2013 Jun; 76():2-13. PubMed ID: 23522791
[TBL] [Abstract][Full Text] [Related]
24. The Search for an Alternative to [
Waldmann CM; Stuparu AD; van Dam RM; Slavik R
Theranostics; 2019; 9(5):1336-1347. PubMed ID: 30867834
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
26. Comparison of gallium-68 somatostatin receptor and
Liu X; Li N; Jiang T; Xu H; Ran Q; Shu Z; Wu J; Li Y; Zhou S; Zhang B
Hell J Nucl Med; 2020; 23(2):188-200. PubMed ID: 32716410
[TBL] [Abstract][Full Text] [Related]
27. Detection of Bone Metastases by
Tian R; Xie Q; Yu F; Du C; Yao X; Zang S; Zhang C; Zhang P; Shao G; Yang Z; Wang F; Yu J
Contrast Media Mol Imaging; 2022; 2022():1750132. PubMed ID: 36447752
[TBL] [Abstract][Full Text] [Related]
28. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide.
Wester HJ; Schottelius M; Scheidhauer K; Meisetschläger G; Herz M; Rau FC; Reubi JC; Schwaiger M
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):117-22. PubMed ID: 12483418
[TBL] [Abstract][Full Text] [Related]
29. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.
Ito T; Jensen RT
Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):15-24. PubMed ID: 27875420
[TBL] [Abstract][Full Text] [Related]
30. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
[TBL] [Abstract][Full Text] [Related]
31. (18)F, (64)Cu, and (68)Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer.
Liu Z; Yan Y; Liu S; Wang F; Chen X
Bioconjug Chem; 2009 May; 20(5):1016-25. PubMed ID: 20540537
[TBL] [Abstract][Full Text] [Related]
32. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.
Breeman WA; de Blois E; Sze Chan H; Konijnenberg M; Kwekkeboom DJ; Krenning EP
Semin Nucl Med; 2011 Jul; 41(4):314-21. PubMed ID: 21624565
[TBL] [Abstract][Full Text] [Related]
33. Nuclear Medicine Imaging of Neuroendocrine Tumors.
Brabander T; Kwekkeboom DJ; Feelders RA; Brouwers AH; Teunissen JJ
Front Horm Res; 2015; 44():73-87. PubMed ID: 26303705
[TBL] [Abstract][Full Text] [Related]
34. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.
Calabrò D; Argalia G; Ambrosini V
Diagnostics (Basel); 2020 Dec; 10(12):. PubMed ID: 33297381
[TBL] [Abstract][Full Text] [Related]
35. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
36. Head-to-Head Comparison of
Zhu W; Cheng Y; Wang X; Yao S; Bai C; Zhao H; Jia R; Xu J; Huo L
J Nucl Med; 2020 Jun; 61(6):897-903. PubMed ID: 31676731
[No Abstract] [Full Text] [Related]
37. Imaging of neuroendocrine tumors.
Rufini V; Calcagni ML; Baum RP
Semin Nucl Med; 2006 Jul; 36(3):228-47. PubMed ID: 16762613
[TBL] [Abstract][Full Text] [Related]
38. ⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.
Ambrosini V; Campana D; Tomassetti P; Fanti S
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1():S52-60. PubMed ID: 22388622
[TBL] [Abstract][Full Text] [Related]
39. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of
Lodge MA; Solnes LB; Chaudhry MA; Wahl RL
Mol Imaging Biol; 2021 Oct; 23(5):766-774. PubMed ID: 33829361
[TBL] [Abstract][Full Text] [Related]
40. The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents.
Smith DL; Breeman WA; Sims-Mourtada J
Appl Radiat Isot; 2013 Jun; 76():14-23. PubMed ID: 23232184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
